Table 2.
GMT* | Seropositive rate (%)** | ||||
---|---|---|---|---|---|
Pre‐immune | Post‐primary | 10 days post‐boost | 21 days post‐boost | ||
PBS/Quil A | 10 ± 0 | 10 ± 0 | 10 ± 0 | 10 ± 0 | 0/0/0 |
HAC1 | |||||
30 μg/Quil A | 10 ± 0 | 17·3 ± 3·7 | 987·6 ± 269·8 | 1810·2 ± 347·3 | 0/100/100 |
15 μg/Quil A | 10 ± 0 | 12·0 ± 1·7 | 1220·1 ± 363·9 | 1810·2 ± 373·3 | 0/100/100 |
5 μg/Quil A | 10 ± 0 | 10·7 ± 0·8 | 712·2 ± 308·9 | 806·3 ± 429·5 | 0/100/100 |
30 μg/Alhydrogel | 10 ± 0 | 10 ± 0 | 232·8 ± 139·2 | 718·4 ± 350·5 | 0/83·3/100 |
HI, hemagglutination inhibition; PBS, phosphate‐buffered saline.
*GMT, geometric mean titer of HI antibodies ± SE.
**Post‐primary/10 days post‐boost/21 days post‐boost.